文献速递血栓与止血

艾美赛珠单抗与免疫抑制治疗获得性血友病A的真实世界影响:美国多中心队列研究

Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort.
PubMed 文献 · Blood Adv · 2024-01-01

该回顾性多中心队列收集美国12家血友病治疗中心62例获得性血友病A患者,均超说明书使用艾美赛珠单抗中位10周。用药后87.1%无新增出血,突破性出血率为每人周0.02(95%CI 0.0-0.03),56%患者抑制物完全消失且FVIII正常化,提示艾美赛珠单抗可提供有效门诊出血预防。

要点

  • 艾美赛珠单抗起始时62.9%患者出血未完全控制,用药后87.1%无新增出血。
  • 55例随访≥12周者突破性出血率每人周0.02(95%CI 0.0-0.03)。
  • 56%患者抑制物完全消失且FVIII正常化,利妥昔单抗治疗者中为63%。

核心结论

  • 艾美赛珠单抗可为获得性血友病A提供有效的门诊出血预防,同步免疫抑制治疗可能进一步减少出血。

研究设计与样本

  • 回顾性多中心队列研究,收集美国12家血友病治疗中心62例获得性血友病A患者去标识化数据,均超说明书使用艾美赛珠单抗,中位用药10周。

主要发现

  • 诊断时95.2%患者有急性出血,艾美赛珠单抗起始时62.9%患者使用止血药物后出血仍为部分控制或未控制。
  • 艾美赛珠单抗起始后87.1%患者无新增出血,5例患者共发生6次突破性出血(其中2次自发性),维持治疗期间无致死性出血事件。
  • 55例随访至少12周患者中,艾美赛珠单抗前12周每人周平均突破性出血率为0.02(95%CI 0.0-0.03)。
  • 上述55例中92.7%接受免疫抑制治疗,74.5%使用含利妥昔单抗方案;总体56%患者抑制物完全消失且FVIII水平正常化,利妥昔单抗治疗者中为63%。
  • 艾美赛珠单抗与免疫抑制治疗的中位停药时间均为18周;2例患者在艾美赛珠单抗治疗期间发生血栓事件,但无不良事件归因于艾美赛珠单抗,也无感染归因于免疫抑制治疗。

关键数值与推荐

  • 艾美赛珠单抗起始后87.1%患者无新增出血。
  • 突破性出血率每人周0.02(95%CI 0.0-0.03),基于55例随访至少12周患者艾美赛珠单抗前12周数据。
  • 抑制物完全消失且FVIII正常化总体56%,利妥昔单抗治疗者63%。
  • 艾美赛珠单抗与免疫抑制治疗中位停药时间均为18周。

临床怎么用

  • 原文结论认为艾美赛珠单抗可为获得性血友病A提供有效的门诊出血预防,同步免疫抑制治疗可能进一步减少出血。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acquired hemophilia A (AHA) is an autoimmune bleeding disorder that is caused by factor VIII (FVIII) autoantibodies with high morbidity and mortality due to bleeding and complications from immunosuppression (IST). To address the real-world implications of the FVIII mimetic antibody, emicizumab, and the role of IST, we retrospectively collected de-identified data on 62 patients with AHA who were treated off-label with emicizumab for a median of 10 weeks at 12 US-based hemophilia treatment centers. Most patients (95.2%) had acute bleeding at diagnosis, and 62.9% had partial or no control of bleeds despite the use of hemostatic agents at the time emicizumab was started. The main reason for initiating emicizumab was outpatient bleeding prophylaxis. After initiation of emicizumab, 87.1% had no additional bleeds. There were 6 breakthrough bleeds (2 spontaneous) in 5 patients and no fatal bleeding events during maintenance emicizumab treatment. The mean breakthrough bleed rate per patient-week was 0.02 (95% confidence interval, 0.0-0.03) during the first 12 weeks of emicizumab for the 55 patients with at least 12 weeks of follow-up. Of these patients, 92.7% received IST and 74.5% were prescribed rituximab-based regimens. Complete resolution of inhibitor and normalization of FVIII levels occurred in 56% overall and in 63% of the patients treated with rituximab. Overall, the median time to discontinuation of emicizumab and IST was 18 weeks. Two patients had thrombotic events while on emicizumab, but no adverse events were attributed to emicizumab and there were no infections attributed to IST. Emicizumab provides effective outpatient bleeding prophylaxis for AHA, and concurrent IST may further mitigate bleeding.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Poston JN, Bryan C, von Drygalski A, et al. Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort. Blood Adv. 2024. PMID: 39361769. doi:10.1182/bloodadvances.2024013882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。